NCT04262804Phase 2Unknown

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Study sponsor: Zai Lab (Shanghai) Co., Ltd.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-09-03Actual
Enrollment · participants123Actual
Source updated2023-08-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview